Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.37 |
| ▸ | AR | P10275 | 7/20 | 0.35 |
| ▸ | PGR | P06401 | 3/20 | 0.35 |
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.34 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.34 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4114375 | 0.91 | MRGPRX4 (0.36) | MRGPRX4ARPGRFFAR4NR3C2 | |
| SCHEMBL4110055 | 0.88 | ALDH1A1 (0.34) | PGRFFAR4 | |
| SCHEMBL4104942 | 0.87 | PGR (0.47) | PGR | |
| SCHEMBL4102622 | 0.85 | MRGPRX4 (0.37) | MRGPRX4ARPGRFFAR4NR3C2 | |
| SCHEMBL4962255 | 0.82 | MRGPRX4 (0.40) | MRGPRX4ARPGRFFAR4NR3C2 | |
| SCHEMBL4114557 | 0.81 | AR (0.37) | MRGPRX4ARPGR | |
| SCHEMBL4104393 | 0.80 | KDM4E (0.34) | PGRFFAR4 | |
| SCHEMBL4106028 | 0.79 | AR (0.46) | AR | |
| SCHEMBL4098285 | 0.78 | PGR (0.48) | MRGPRX4ARPGRFFAR4NR3C2 | |
| SCHEMBL4102882 | 0.77 | PGR (0.47) | PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090099209-A1 | Compounds Useful in Therapy | PFIZER INC | 2009-04-16 | — | — | US | disclosed |
| US-7482375-B2 | Compounds useful in therapy | PFIZER INC. (US) | 2009-01-27 | — | — | US | disclosed |
| US-20060241125-A1 | Compounds useful in therapy | BRADLEY PAUL A | 2006-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241125-A1 | Compounds useful in therapy | CBR3, GPER1, CBR1 | MRGPRX4 218/4885AR 387/4885PGR 57/4885 |
| US-20090099209-A1 | Compounds Useful in Therapy | CBR3, CBR1, GPER1 | MRGPRX4 262/4885AR 400/4885PGR 87/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.